Every material Form 8-K XBiotech Inc. filed with the SEC in 2026, read and summarized by AI: what happened, the key figures, whether it reads positive or negative for shareholders, and how big a deal it is (impact 1-5). Newest first; each brief links to its own page and to the filing on SEC.gov.
XBiotech's board appointed Dr. Sushma Shivaswamy, who had been interim CEO since December 2025 and remains Chief Scientific Officer, and Jan-Paul Simard as co-chief executive officers effective October 23, 2026. Simard is the son of founder John Simard, and his employment agreement includes a one-time grant of 2,000,000 stock options, which shareholders may weigh alongside the leadership change.
Dr. Sushma Shivaswamy, 48, has been with XBiotech for 17 years and will continue as Chief Scientific Officer with an annual salary of $750,000.
Jan-Paul Simard, 24, joined in 2012; his Executive Employment Agreement is dated October 26, 2026, with a base salary of $150,000, prorated through the end of 2026.
Simard's initial grant is 2,000,000 stock options, exercisable over ten years and vesting over three years in six-month intervals.
Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.
Only material 8-Ks get a brief: results, deals, executive changes, restructuring, impairments, delisting notices, restatements, cybersecurity incidents and other disclosed events. Routine filings (vote results, exhibits only) are skipped. Every XBiotech Inc. filing is on SEC EDGAR ↗. 8-K briefs of other companies →